Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616

Pallavi Madhiraju- August 25, 2023 0

Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a novel, oral proprotein convertase subtilisin/kexin type 9 ... Read More

AstraZeneca acquires oral PCSK9 inhibitors from Dogma Therapeutics

pharmanewsdaily- September 19, 2020 0

Pharma giant AstraZeneca has signed a deal to acquire a preclinical oral PCSK9 inhibitor asset from Dogma Therapeutics, a portfolio company of Viva Biotech. The ... Read More